{"title":"gB纳米粒子疫苗引发针对EBV的保护性中和抗体反应。","authors":"Cong Sun, Yin-Feng Kang, Xin-Yan Fang, Yi-Na Liu, Guo-Long Bu, Ao-Jie Wang, Yan Li, Qian-Ying Zhu, Hua Zhang, Chu Xie, Xiang-Wei Kong, Yong-Jian Peng, Wen-Jie Lin, Ling Zhou, Xin-Chun Chen, Zheng-Zhou Lu, Hui-Qin Xu, Dong-Chun Hong, Xiao Zhang, Ling Zhong, Guo-Kai Feng, Yi-Xin Zeng, Miao Xu, Qian Zhong, Zheng Liu, Mu-Sheng Zeng","doi":"10.1016/j.chom.2023.09.011","DOIUrl":null,"url":null,"abstract":"<p><p>Epstein-Barr virus (EBV) is a global public health concern, as it is known to cause multiple diseases while also being etiologically associated with a wide range of epithelial and lymphoid malignancies. Currently, there is no available prophylactic vaccine against EBV. gB is the EBV fusion protein that mediates viral membrane fusion and participates in host recognition, making it critical for EBV infection in both B cells and epithelial cells. Here, we present a gB nanoparticle, gB-I53-50 NP, that displays multiple copies of gB. Compared with the gB trimer, gB-I53-50 NP shows improved structural integrity and stability, as well as enhanced immunogenicity in mice and non-human primate (NHP) preclinical models. Immunization and passive transfer demonstrate a robust and durable protective antibody response that protects humanized mice against lethal EBV challenge. This vaccine candidate demonstrates significant potential in preventing EBV infection, providing a possible platform for developing prophylactic vaccines for EBV.</p>","PeriodicalId":93926,"journal":{"name":"Cell host & microbe","volume":" ","pages":"1882-1897.e10"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV.\",\"authors\":\"Cong Sun, Yin-Feng Kang, Xin-Yan Fang, Yi-Na Liu, Guo-Long Bu, Ao-Jie Wang, Yan Li, Qian-Ying Zhu, Hua Zhang, Chu Xie, Xiang-Wei Kong, Yong-Jian Peng, Wen-Jie Lin, Ling Zhou, Xin-Chun Chen, Zheng-Zhou Lu, Hui-Qin Xu, Dong-Chun Hong, Xiao Zhang, Ling Zhong, Guo-Kai Feng, Yi-Xin Zeng, Miao Xu, Qian Zhong, Zheng Liu, Mu-Sheng Zeng\",\"doi\":\"10.1016/j.chom.2023.09.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Epstein-Barr virus (EBV) is a global public health concern, as it is known to cause multiple diseases while also being etiologically associated with a wide range of epithelial and lymphoid malignancies. Currently, there is no available prophylactic vaccine against EBV. gB is the EBV fusion protein that mediates viral membrane fusion and participates in host recognition, making it critical for EBV infection in both B cells and epithelial cells. Here, we present a gB nanoparticle, gB-I53-50 NP, that displays multiple copies of gB. Compared with the gB trimer, gB-I53-50 NP shows improved structural integrity and stability, as well as enhanced immunogenicity in mice and non-human primate (NHP) preclinical models. Immunization and passive transfer demonstrate a robust and durable protective antibody response that protects humanized mice against lethal EBV challenge. This vaccine candidate demonstrates significant potential in preventing EBV infection, providing a possible platform for developing prophylactic vaccines for EBV.</p>\",\"PeriodicalId\":93926,\"journal\":{\"name\":\"Cell host & microbe\",\"volume\":\" \",\"pages\":\"1882-1897.e10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell host & microbe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.chom.2023.09.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell host & microbe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.chom.2023.09.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV.
Epstein-Barr virus (EBV) is a global public health concern, as it is known to cause multiple diseases while also being etiologically associated with a wide range of epithelial and lymphoid malignancies. Currently, there is no available prophylactic vaccine against EBV. gB is the EBV fusion protein that mediates viral membrane fusion and participates in host recognition, making it critical for EBV infection in both B cells and epithelial cells. Here, we present a gB nanoparticle, gB-I53-50 NP, that displays multiple copies of gB. Compared with the gB trimer, gB-I53-50 NP shows improved structural integrity and stability, as well as enhanced immunogenicity in mice and non-human primate (NHP) preclinical models. Immunization and passive transfer demonstrate a robust and durable protective antibody response that protects humanized mice against lethal EBV challenge. This vaccine candidate demonstrates significant potential in preventing EBV infection, providing a possible platform for developing prophylactic vaccines for EBV.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
